Literature DB >> 6103058

Metabolite involvement in bromocriptine-induced circling behaviour in rodents.

C Reavill, P Jenner, C D Marsden.   

Abstract

Bromocriptine and apomorphine produced identical circling responses in rodents with medial forebrain bundle lesions. Rotation induced by bromocriptine, but not by apomorphine, was inhibited by prior treatment with reserpine or alpha-methyl-p-tyrosine suggesting a requirement for intact presynpatic events. Bromocriptine-induced circling also was inhibited by the catecholamine re-uptake blockers nomifensine and desmethylimipramine, supporting the role of presynaptic mechanisms. Bromocriptine-induced circling, but not apomorphine circling, was reduced by pre-treatment with SKF 525A, an inhibitor of monooxygenase enzymes, suggesting metabolite involvement in the turning response. This compound prolonged hexobarbitone sleeping times and zoxazolamine paralysis times in mice. These indices of drug metabolizing activity also were prolonged by pre-treatment with desmethylimipramine while nomifensine prolonged only hexobarbitone sleeping times and alpha-methyl-p-tyrosine had no effect on either index. The data suggest that a metabolite of bromocriptine may be of importance in causing circling and that uptake of bromocriptine (or a metabolite) into presynaptic catecholamine terminals may be necessary.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6103058     DOI: 10.1111/j.2042-7158.1980.tb12912.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  8 in total

1.  Bromocriptine induces marked locomotor stimulation in dopamine-depleted mice when D-1 dopamine receptors are stimulated with SKF38393.

Authors:  D M Jackson; M Hashizume
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

Review 2.  The motor effects of bromocriptine--a review.

Authors:  D M Jackson; O F Jenkins; S B Ross
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

Review 3.  Hypothesis: bromocriptine lacks intrinsic dopamine receptor stimulating properties.

Authors:  D M Jackson; O F Jenkins
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

Review 4.  Anti-parkinsonian drugs today.

Authors:  N P Quinn
Journal:  Drugs       Date:  1984-09       Impact factor: 9.546

5.  Bromocriptine potentiates the behavioural effects of directly and indirectly acting dopamine receptor agonists in mice.

Authors:  O F Jenkins; D M Jackson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-10       Impact factor: 3.000

6.  Effects of three dopamine agonists on cage climbing behavior.

Authors:  G Gianutsos; J L Palmeri
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

7.  Bromocriptine-induced locomotor stimulation in mice is modulated by dopamine D-1 receptors.

Authors:  D M Jackson; M Hashizume
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

8.  Microdialysis study of bromocriptine and its metabolites in rat pituitary and striatum.

Authors:  S Granveau-Renouf; D Valente; A Durocher; J M Grognet; E Ezan
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Apr-Jun       Impact factor: 2.569

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.